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Abstract
The ookinete surface protein Pfs25 is a macrogamete-to-ookinete/ookinete stage antigen of Plasmodium falciparum,
capable of exerting high-level anti-malarial transmission-blocking activity following immunization with recombinant
protein-in-adjuvant formulations. Here, this antigen was expressed in recombinant chimpanzee adenovirus 63 (ChAd63),
human adenovirus serotype 5 (AdHu5) and modified vaccinia virus Ankara (MVA) viral vectored vaccines. Two
immunizations were administered to mice in a heterologous prime-boost regime. Immunization of mice with AdHu5
Pfs25 at week 0 and MVA Pfs25 at week 10 (Ad-MVA Pfs25) resulted in high anti-Pfs25 IgG titers, consisting of predominantly
isotypes IgG1 and IgG2a. A single priming immunization with ChAd63 Pfs25 was as effective as AdHu5 Pfs25 with respect to
ELISA titers at 8 weeks post-immunization. Sera from Ad-MVA Pfs25 immunized mice inhibited the transmission of P.
falciparum to the mosquito both ex vivo and in vivo. In a standard membrane-feeding assay using NF54 strain P. falciparum,
oocyst intensity in Anopheles stephensi mosquitoes was significantly reduced in an IgG concentration-dependent manner
when compared to control feeds (96% reduction of intensity, 78% reduction in prevalence at a 1 in 5 dilution of sera). In
addition, an in vivo transmission-blocking effect was also demonstrated by direct feeding of immunized mice infected with
Pfs25DR3, a chimeric P. berghei line expressing Pfs25 in place of endogenous Pbs25. In this assay the density of Pfs25DR3
oocysts was significantly reduced when mosquitoes were fed on vaccinated as compared to control mice (67% reduction of
intensity, 28% reduction in prevalence) and specific IgG titer correlated with efficacy. These data confirm the utility of the
adenovirus-MVA vaccine platform for the induction of antibodies with transmission-blocking activity, and support the
continued development of this alternative approach to transmission-blocking malaria subunit vaccines.
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Introduction
Despite considerable progress in efforts to control the transmis-
sion of malaria, the disease continues to cause approximately 225
million cases of clinical illness and nearly eight hundred thousand
deaths each year [1]. The majority of severe disease in humans is
caused by the Plasmodium falciparum parasite, transmitted exclusively
by Anopheles mosquitoes. Insecticide treated nets (ITNs) can be used
to interrupt the transmission cycle and have been shown in trials to
reduce child mortality by 17% [2]. However ITNs do not appear to
be as effective in protecting older children against febrile malaria
[3]. Additional means of reducing malaria transmission thus remain
urgently required to expand our armamentarium, including the
development of an effective vaccine.
The most advanced malaria subunit vaccine, RTS,S/AS01, can
induce 30–50% efficacy against clinical malaria, likely due to the
generation of high titer antibodies against sporozoites [4]. This,
along with the introduction of partially effective pre-erythrocytic
control measures (e.g. ITNs, indoor residual spraying (IRS),
artemisinin-based combination therapies (ACTs)), has led to a
renewed interest in developing transmission-blocking vaccines
(TBVs) – an approach that intercepts the P. falciparum life-cycle
within the mosquito. This ‘‘community vaccination’’ approach
would complement partially effective pre-erythrocytic control
measures, and the development of an effective TBV is now widely
viewed as essential for breaking the transmission cycle of malaria,
especially following recent ambitious calls that the malaria
community should aim for elimination or eradication [5].
A number of antigenic targets that induce transmission-blocking
activity (TBA) in malaria have been investigated over the last 20
years [6,7]. At present, the TBV immunogen which has been most
widely studied and for which evidence is most compelling is the
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29428
ookinete surface protein P25, although other parasitic (P48/45,
P230, HAP2) and mosquito Anopheles gambiae aminopeptidase N
(AgAPN1) antigens remain promising candidate targets [8,9,10,
11]. Antigen P25 in P. falciparum (Pfs25) is expressed in the
macrogamete-to-ookinete stages of the parasite in the mosquito
vector, and monoclonal antibodies against this antigen inhibit
transmission [12]. This observation was subsequently translated
into effective candidate subunit vaccines against malaria trans-
mission in animal models [13,14,15]. Efficacy of transmission
blockade was found to relate directly to ELISA titers, thus
providing a relatively simple means of reliably estimating
candidate vaccine efficacy [16]. Proof of principle of transmission
blockade has also been established in humans using candidate P.
falciparum and P. vivax P25 vaccines but unfortunately vaccines that
have induced high titer antibodies were formulated in an adjuvant
that appeared to be unsuitable for widespread human use, with an
unacceptable incidence of side effects [17]. The development of a
P25 protein vaccine has thus been hampered by the not
uncommon issues surrounding the clinical suitability of various
experimental adjuvants – including toxicity, low-level potency or
lack of availability for commercial development, e.g. Freund’s
adjuvant, aluminium hydroxide, outer-membrane proteins and
cholera toxin [18,19,20].
In recent years, the pre-clinical development of viral vectored
blood-stage malaria vaccines has shown that moderately high level
antibody responses can be induced by this alternative vaccine
platform in mice [21,22,23], rabbits [24,25] and rhesus macaques
[26]. Antibody-mediated protection could be achieved against the
P. yoelii mouse model of blood-stage malaria infection by using a
priming immunization with an adenovirus vector followed by a
booster immunization with the poxvirus vector MVA, and this
approach targeting the blood-stage malaria antigens merozoite
surface protein 1 (MSP1) and apical membrane antigen 1 (AMA1)
has since entered Phase I/IIa clinical trials [27], showing this
regime to be safe and similarly immunogenic in humans [28].
Viral vectored vaccines have a large insert capacity, allowing for
entire proteins to be inserted under the control of well
characterized promoters that drive high-level transgene expres-
sion, leading to potent vaccine immunogenicity. These viruses can
be quickly expanded in vitro and purified for pre-clinical use, where
they are administered intramuscularly in saline without the need
for any chemical adjuvant [27,29]. Immunization of mice with
four doses of a recombinant human adenovirus 5 expressing the P.
vivax homologue, Pvs25, led to antibody induction and TBA
against P. vivax [30]. This success supports the use of a similar
approach against P. falciparum using viral vectors expressing Pfs25.
The Pfs25 antigen is comprised of four EGF-like domains [31].
Allelic replacement studies suggest functional conservation be-
tween diverse Plasmodium species [32,33]. Chimeric parasite lines
of P. berghei expressing Pfs25 (TrPfs25Pb) and Pvs25 (Pvs25DR3)
have been developed, and provide a suitable in vivo model for the
assessment of vaccines targeting P25 [32,33,34,35]. The approach
of using transgenic rodent malarial parasites to assess the immune
system’s response to targets from a human malarial parasite has
been additionally described in previous studies [36]. Such chimeric
parasite lines provide a safe, cheap and more practical alternative
to the use of non-human primate models for pre-clinical challenge
studies of malaria vaccine efficacy. We have thus investigated the
use of a similar transgenic model (Pfs25DR3) to test the efficacy of
a heterologous prime-boost viral vectored P. falciparum Pfs25
vaccine regime in vivo. This approach to the assessment of anti-
malarial transmission-blocking antibody activity is compared to
the commonly used standard membrane-feeding assay (SMFA). In
the SMFA, immune sera are mixed with P. falciparum gametocytes
and the mixture is fed to mosquitoes via membrane feeders. Whilst
this ex vivo assay provides useful information regarding the
functional activity of antibodies, and is the ‘‘gold-standard’’ assay
for assessing TBA, it is time-consuming, expensive and its use is
limited to laboratories with access to P. falciparum culture facilities.
As demonstrated by others [32,33,34,36,37] we have found
chimeric parasites provide a simple in vivo challenge model, which
can be used to investigate biological responses to parasites and to
measure the efficacy of vaccines at the pre-clinical stage.
Here we evaluate, both in vivo and ex vivo, the ability of a
heterologous prime-boost viral vectored Pfs25 vaccine regime to
induce an anti-malarial transmission-blocking response. We show
that immunization with AdHu5 Pfs25 elicits anti-Pfs25-specific
IgG responses. Given the use of the AdHu5 vector may be limited
in humans [38], a simian adenoviral vectored prime expressing
Pfs25 was also developed. The use of a chimpanzee adenovirus 63
prime (ChAd63 Pfs25) was found to elicit comparable ELISA titers
to AdHu5 Pfs25 at 8 weeks post-immunization. Immunization
with AdHu5 Pfs25 prime, MVA Pfs25 boost (Ad-MVA Pfs25) also
confers significant TBA – assessed by both the active immuniza-
tion of mice challenged with transgenic P. berghei expressing Pfs25
(Pfs25DR3), and SMFA on cultured, sexually mature P. falciparum
gametocytes. Our results demonstrate that a viral vectored,
heterologous prime-boost regime against Pfs25 provides a
promising adjuvant-free vaccine delivery platform, and as such
could be considered as a potential tool for the development of
future anti-malarial TBVs.
Materials and Methods
Ethics Statement
All procedures were performed in accordance with the terms of
the UK Animals (Scientific Procedures) Act Project Licence and
were approved by the University of Oxford Animal Care and
Ethical Review Committee (PPL 30/2414) and the Imperial College
Ethical Review Committee (PPL 70/6347). The Office of
Laboratory Animal Welfare (OLAW) Assurance for Imperial
College covers all Public Health Service (PHS) supported activities
involving live vertebrates in the US (#A5634-01). Pooled human
red blood cells and sera were purchased from the National Blood
Service (UK). No ethics approval was therefore obtained for the use
of human sera or red blood cells specifically but the Imperial College
Ethical Review Committee reviewed all the procedures undertaken.
Virus generation
The vaccine antigen used was encoded by pfs25 from the NF54
isolate (GenBank X07802), commenced at amino acid 22 (aa)
(alanine) and truncated prior to the transmembrane domain at aa
193 (threonine). To remove potential N-glycosylation sites,
asparagines at aa sites 112, 165 and 187 were substituted with
glutamine. The final antigen insert was codon optimized for
mammalian expression and synthesized by GeneArt GmbH
(Regensburg, Germany), and fused in frame to the human tissue
plasminogen activator (tPA) leader sequence (GenBank Accession
No. K03021) [21]. Insertion of the gene encoding Pfs25 into
human adenovirus serotype 5 (AdHu5), chimpanzee adenovirus
63 (ChAd63) and modified vaccinia virus Ankara (MVA) was
performed using methods previously described for other antigen
inserts [21,25]. Control AdHu5 and MVA vectors expressing GFP
have been described previously [22].
Pfs25 ELISA
ELISAs against Pfs25 were performed according to a standard-
ized protocol [39] using a reference standard [40]. Protein antigen
Viral Vector Vaccine against Malaria Transmission
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was provided by Dr Y. Wu (NIAID, NIH, USA). Test sera were
diluted to 1:100 or 1:1000 in dilution buffer. Naı¨ve sera were
diluted to 1:100 in dilution buffer and applied to 8 wells per plate.
Positive control sera were provided by Dr Y. Wu (NIAID, NIH,
USA) and were serially diluted on each plate to provide a standard
curve. The ELISA units of this reference positive control sera was
taken to be 14700. All sera (except naı¨ve) were applied in duplicate
and diluted 3-fold. Positive reference sera were applied to all
plates. Plates were read after 20 minutes incubation in the dark at
room temperature (RT). Reference sera diluted 1:14700 gave an
expected absorbance at 405 nm (OD405) of 1.0 at this time-point.
A standard curve was prepared for each plate using the reference
sera. The curve was plotted using a 4-parameter equation and
plates were only accepted for further analysis if R2.0.998. The
reference serum reading was taken to be at 14700 ELISA units.
Using the OD405 values of test sera at the steep part of the curve
(0.2–0.8), the ELISA units for each sample were calculated. The
final result was the mean of the ELISA units calculated at a range
of dilutions. Alternatively bound antibody isotypes were detected
using biotin-conjugated rat anti-mouse IgG1, IgG2a, IgG2b or
IgG3 follower by ExtrAvidin alkaline phosphatase conjugate using
methods previously described [21]. The OD405 was read at a
dilution of 1 in 500 and classed as no detectable antibody if the
OD was then equal to or less than a non-immune naı¨ve sample. A
reference sample was also included on each plate as an internal
positive control.
Construction of Pfs25DR3
This transgenic line was constructed using previously published
methods [32]. The targeting plasmid (kindly donated by Prof. N.
Kumar, John Hopkins University, USA) was linearized by KpnI
and NotI restriction digestion, and 10 mg was transfected into P.
berghei ANKA 2.34 using the Amaxa human T cell nucleofactor kit
as described previously [41]. Parasites were injected intraperito-
neally (i.p.) into mice; 24 hours later mice were given drinking
water containing 0.07 mg/ml pyrimethamine to select for drug
resistant transfectants. Drug resistant parasites were taken through
two successive rounds of selection, subjected to diagnostic PCR to
confirm 59/39 integration and presence of Pfs25. Limiting dilution
cloning was then carried out to create the transgenic parasite
Pfs25DR3. Clones were again subjected to diagnostic PCR to
confirm 59/39 integration, absence of Pbs25 and presence of Pfs25.
The following primer pairs were used to detect 59 integration of
cassette, 39 integration of cassette, presence of Pfs25 and absence
of Pbs25 respectively.
(Primers: Int1 59-CAT AGG GAT ATT TAC ATA CTC
CTC-39/Int2 59-CAA ACA TTA TTT ACC ATA TCA TAT
CC-39/Int3 59-CAA TGA TTC ATA AAT AGT TGG -39/Int4
59-GGT GGA AAA ACG CCC CCA AAT C-39/Pfs25F 59-AGT
TAC CGT GGA TAC TGT ATG G-39/Pfs25R 59-CTG AAA
AAG CAG TAC ATA TAG AGC-39/Pbs25F 59-GCG AGA
TCT ATG AAT ACT TAT TAC AGT GTT TTT CTT-39/
Pbs25R 59-GCG CCT AGA ATG ATA TTT GAA AAT ATT
AGT AAA ATG AC-39).
Parasite maintenance
Routine parasite maintenance was carried out as previously
described [42]. P. berghei ANKA 2.34 or P. berghei Pfs25DR3
parasites were maintained in 4–10 week old female Tuck Ordinary
(TO) mice by serial blood passage (up to a maximum of 8
passages). Hyper-reticulocytosis was induced 2–3 days before
infection by treating mice with 200 ml i.p. phenylhydrazinium
chloride (PHz; 6 mg/ml in PBS; ProLabo, UK). Mice were
infected by i.p. injection and infections were monitored on
Giemsa-stained tail blood smears as described previously [42].
Western blotting
P. berghei ookinetes from wild-type ANKA 2.34 and transgenic
Pfs25DR3 were cultured and purified as described previously [33].
Samples were then analyzed by SDS-PAGE under reducing
conditions, and western blot, using either pooled anti-AdHu5
Pfs25 (1:500), or vector control pooled anti-AdHu5 GFP [22]
serum (1:500) followed by ECLTM sheep anti-mouse IgG (GE
Healthcare) as a secondary antibody at a dilution of 1:10,000. For
loading controls, nitrocellulose membranes were probed using
anti-TAT-1 (anti-a tubulin) antibody at 1:10,000 (primary), and
sheep anti-mouse IgG (GE Healthcare) at a dilution of 1:10,000 as
the secondary antibody.
Immunofluorescence Assay
Expression and localisation of Pfs25 in the Pfs25DR3 transgenic
parasite was confirmed via immunofluorescence assay on para-
formaldehyde (PFA) fixed ookinetes. Briefly, Pfs25DR3 ookinete
cultures were washed twice in ookinete media and then taken up in
a 1:1 mixture of ookinete medium and fetal bovine serum [8].
Smears were made and air-dried. Slides were fixed for 10 min in
4% PFA in PBS, and washed once with tris-buffered saline (TBS).
Slides were blocked for 60 min in blocking buffer (10% v/v goat
serum, 1% w/v BSA in PBS), following which, slides were washed
once in TBS and incubated overnight at 4uC in a wet chamber
with a reference mouse anti-Pfs25 antibody 4B7 (1 in 500) in 1%
(w/v) BSA in TBS. The next day, slides were washed three times
in TBS, incubated with Alexa Flour 488-labelled goat anti-mouse
IgG (1:1500 in 1% w/v BSA in TBS) for 45 min, washed three
times in TBS, mounted with Vectashield/DAPI and analyzed by
fluorescence microscopy.
Active immunization
Groups of 15 mice were immunized for challenge experiments
and divided randomly into groups of 5 mice for wild-type P. berghei
challenge and groups of 10 mice for challenge with Pfs25DR3. For
experiments to determine serology alone, groups of 10 mice were
used. A single experiment to determine the immunogenicity of
ChAd63 Pfs25 was performed using 25 mice in one group. Female
BALB/c mice were 6–8 weeks of age at the start of the
experiments (Harlan, UK). Mice were immunized intramuscularly
(i.m.). Doses of vaccine used were 161010 viral particles (vp) of the
AdHu5 or ChAd63 vaccines at week 0 and 16107 plaque forming
units (pfu) of the MVA vaccines at week 10. Control mice were
immunized with AdHu5 and MVA expressing GFP as an
irrelevant antigen in place of Pfs25 (Ad-MVA GFP) [22]. Viral
vectored vaccines were prepared in sterile, endotoxin-free PBS
prior to immunization. Sera were collected at 2, 8, 10 and 12
weeks following the initial immunization. In a repeat experiment
sera were collected at week 12 only. Following ChAd63 Pfs25
immunization sera were collected at week 8 only.
For challenge experiments, two groups of fifteen mice were
immunized. One group was immunized intramuscularly (i.m.)
with 161010 vp AdHu5 Pfs25 at week 0 and 16107 pfu MVA
Pfs25 at week 10. The second (control) group was similarly
immunized with Ad-MVA GFP control. At week 12 post-
immunization, mice were PHz treated, and three days later
infected i.p. with 106 P. berghei ANKA 2.34 or P. berghei Pfs25DR3.
In each group, 10 mice were challenged with Pfs25DR3, to assess
anti-Pfs25 mediated transmission-blockade, and 5 mice were
challenged with P. berghei ANKA 2.34, to assess potential non-
specific transmission-blockade effects. Three days post-infection,
Viral Vector Vaccine against Malaria Transmission
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.50 starved A. stephensi mosquitoes were allowed to feed on each
infected mouse. 24 hours after feeding, mosquitoes were briefly
anesthetized with CO2, and those that had not fed were removed.
Mosquitoes were then maintained on fructose [8% (w/v) fructose,
0.05% (w/v) p-aminobenzoic acid] at 19–22uC and 50–80%
relative humidity. On day 12 post-feeding, mosquito midguts were
dissected, and oocyst prevalence and intensity recorded. For each
mouse, oocyst numbers were counted and a calculation was made
of mean oocyst intensity. For inhibition calculations this number
was compared to mean oocyst intensity and infection prevalence in
mice immunized with Ad-MVA GFP control. All care and
handling of animals was in accordance with the Guidelines for
Animal Care and Use prepared by Imperial College London.
P. falciparum SMFA
For P. falciparum infections, erythrocytic stages of the NF54
isolate were cultured as described previously [43] followed by
induction of gametocytogenesis [44]. Ten to 18 day old cultures
demonstrating exflagellation of male gametocytes were then added
to fresh human red blood cells (RBCs, group A, National Blood
Service, UK) with heat-inactivated human AB serum (National
Blood Service, UK) at a packed cell volume of ,40%, and
introduced into membrane feeders mixed with serum from mice
harvested 12 weeks post-immunization at final dilutions of 1 in 5, 1
in 10 and 1 in 100. Sera from mice immunized with AdHu5 and
MVA expressing GFP were used as a negative control. Anopheles
stephensi mosquitoes of strain SDA500 were exposed to the
membrane feeders for 25–30 min, and thereafter kept at 26uC
and 80% relative humidity until dissection. Mosquito midguts
were dissected 12 days post infection, stained with 0.5%
mercurochrome and examined for oocysts using light microscopy.
Transmission-blockade was assessed as reduction in mean oocyst
intensity/prevalence in feeds supplemented with anti-Pfs25 sera, in
comparison with negative control feeds at corresponding serum
dilutions.
Statistics
Statistical significance was analyzed using Prism (version 5).
Antibody titers were log-transformed to enable parametric
analysis. Where data were normally distributed parametric tests
were used for data analysis. Where a mouse was tested over time,
paired t-tests were used to compare ‘pre-boost’ (week 10) titers
with ‘post-boost’ (time-points $12 week) titers. Parametric data
were analyzed using a t-test or one-way ANOVA with Bonferro-
ni’s multiple comparison test. Correlations were tested using non-
parametric Spearman rank correlations. Significance was taken as
*P,0.05, **P,0.01 and ***P,0.001.
Results
Pfs25 specific total and isotype IgG responses following
Ad-MVA Pfs25 immunization
Ten BALB/c mice were immunized with 161010 vp AdHu5
Pfs25 at week 0 and 16107 pfu MVA Pfs25 at week 10 (Ad-MVA
Pfs25). A second group of ten BALB/c mice were immunized with
161010 vp AdHu5 GFP at week 0 and 16107 pfu MVA GFP at
week 10 (Ad-MVA GFP) as vector controls expressing an
irrelevant antigen. Sera were taken at 2, 8 and 10 weeks following
the first immunization and two weeks following the final
immunization for measurement of total IgG responses against
recombinant Pfs25 by ELISA. A further group of fifteen BALB/c
mice were immunized in a repeat experiment in which sera were
only taken at week 12. As found with previous mouse
immunization studies for the blood-stage antigen MSP1 [21,25],
antibody titers increased over time following the recombinant
AdHu5 immunization (figure 1a). There was a significant increase
in titer from week 2 to week 10 (P,0.01) and a further significant
increase in titers following the MVA boost (week 10 to week 12,
P,0.05). The increase in titer from week 2 to week 12 was highly
significant (P,0.001). The geometric mean titer at week 12 did not
differ significantly between mice immunized in the replicated
studies. Data from repeat studies combined, as statistical analysis
permitted, to give a geometric mean titer at week 12 of 1664 (95%
CI 1180–2345) ELISA units. The use of the standardized ELISA
assay and a reference serum was performed to allow comparison of
results obtained in this study with those analyzed using the same
methodology [39]. At week 12, 96% of Ad-MVA Pfs25
immunized mice had antibody titers greater than 600 ELISA
units, the level of polyclonal mouse serum expected to give 50%
efficacy against P. falciparum in a SMFA [40]. No Pfs25 antibodies
Figure 1. Pfs25 specific total IgG responses following Ad-MVA
Pfs25 and ChAd63 Pfs25 immunization. (A) BALB/c mice were
immunized with Ad-MVA Pfs25 (AdHu5 Pfs25 prime, MVA Pfs25 boost).
Total IgG responses against recombinant Pfs25 protein were measured
by ELISA in the serum of mice taken at the number of weeks following
first immunization as shown. Mean ELISA titers 6 sem (n= 10) are
shown. Titers increased over time following the first immunization and
were boosted following MVA Pfs25 administration at week 10 (arrow).
The dotted line represents the titer required to provide 50% efficacy
against P. falciparum in a SMFA using alternative vaccine platforms,
according to previously published methods. (B) BALB/c mice were
immunized with ChAd63 Pfs25 (n = 25) or AdHu5 Pfs25 (n = 10). Total
IgG responses against recombinant Pfs25 protein were measured by
ELISA in the serum of mice taken 8 weeks following a single
immunization. Geomean ELISA titers 695% CI are shown.
doi:10.1371/journal.pone.0029428.g001
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were detected in sera taken from GFP vector control immunized
mice.
To examine the utility of a simian adenoviral vector in a similar
context, mice were immunized with ChAd63 Pfs25 and sera were
taken at 8 weeks prior to MVA Pfs25 boosting. These samples
were analyzed by ELISA and compared to the samples following
AdHu5 Pfs25 immunization. There was no significant difference
in titer from results at this time-point following AdHu5 Pfs25, by t-
test of log-transformed data (P = 0.08, figure 1b). IgG isotype
analysis following Ad-MVA Pfs25 immunization showed a mixed
T helper type 1 (Th1)/Th2 IgG response with comparable levels of
IgG2a and IgG1 (figure 2). Lower levels of IgG2b were also
observed but IgG3 was not detectable. Similar IgG isotype profiles
following Ad-MVA immunization have been observed in other
murine studies with vectors encoding blood-stage malaria
antigens[21,24,25].
Generation and phenotypic analysis of Pfs25DR3
To evaluate TBA in vivo, we created a transgenic P. berghei where
the P. berghei open reading frames P25 and P28 were replaced with
the P. falciparum gene sequence of Pfs25 and the selectable marker
cassette (TgDHFR/TS). This was based on previously published
chimeras [32,33]. A schema of the process used is shown
(figure 3a). Successful transfer of the selectable marker cassette
was confirmed by PCR (figure 3b). An important caveat to the
design and use of transgenic reporter parasite lines is that great
care has to be taken to ensure that the anticipated antigenic target
is the only potential target expressed by the reporter parasite,
simple replacement of the homologous gene may not be adequate.
In this case, the cross reactivity of antibodies to Pfs25 with Pbs28
was overcome by use of a construct that simultaneously removed
both the homologous, and the paralogous, potentially ‘cross-
reactive’ gene when the new target gene was inserted. This
excluded the possibility of cross-reactive epitopes, conserved
between Pfs25 and Pbs28 causing a non-vaccine specific
transmission-blocking effect. The parasite is still fully viable
throughout the entire lifecycle, as expected due to the (previously
demonstrated) overlapping, partially redundant functions of P25
and P28 [45].
Serum harvested as described above was also assessed for its
ability to recognize Pfs25 protein by Western blot (figure 3c) and
immunofluorescence assays (figure 3d). Westerns on cultured and
purified ookinetes from P. berghei Pfs25DR3, when probed with
pooled anti-Pfs25 sera, produced a clear and distinct band at
,25 kDa, indicating recognition of parasite expressed Pfs25. A
corresponding band was not observed with purified P. berghei
ANKA 2.34 wild-type (WT) ookinetes, indicating species-specific
recognition of Pfs25 from the chimeric parasite. Blots on both WT
2.34 and Pfs25DR3 ookinetes using negative control serum from
mice immunized with GFP vector control viruses were invariably
negative. Immunofluorescence assay analysis using PFA fixed
ookinetes confirmed the specific appropriate expression and
localization of Pfs25 in the Pfs25DR3 transgenic parasite.
Parasite infectivity following Ad-MVA Pfs25
immunization
Two groups of fifteen BALB/c mice were immunized as above
with Ad-MVA Pfs25 or Ad-MVA GFP vector controls. Following
the collection of sera from the Ad-MVA Pfs25 group for antibody
ELISA, ten mice per group were subsequently infected with P.
berghei Pfs25DR3, whilst five mice per group were infected with P.
berghei wild-type (as controls to detect any potential non-Pfs25
dependent transmission-blockade). Direct feeds on immunized
mice revealed significant inhibition of Pfs25DR3 oocyst intensity
in mosquitoes fed on Ad-MVA Pfs25 immunized mice in
comparison to controls. Mean oocyst number was reduced by
67% inhibition (P,0.001, figure 4a). Correspondingly, mean
infection prevalence was reduced from 93% to 67%, a reduction
in prevalence of 28% (P = 0.001, figure 5a). There was no
significant reduction in wild-type P. berghei oocyst production when
comparing mice immunized with Ad-MVA Pfs25 versus Ad-MVA
GFP vector immunized controls (P.0.05) (figures 4b and 5b). A
significant correlation was found between log-transformed total
IgG and number of oocysts (Spearman rank correlation;
P = 0.0008, r =20.87, n = 10, figure 6, circles) and prevalence of
infection (Spearman rank correlation; P = 0.01, r = 0.73, n = 10,
figure 6, squares). No significant correlation was found between
log-transformed IgG1, IgG2a or IgG2b, IgG1:IgG2a ratio and
number of oocysts or prevalence of infection.
To further determine the functional efficacy of antibodies
induced by Ad-MVA Pfs25 immunization, a SMFA with P.
falciparum (NF54 strain) was performed. Antisera from one
representative mouse immunized with Ad-MVA Pfs25 and one
Ad-MVA GFP control were tested for their ability to block oocyst
development. Antiserum from the Ad-MVA Pfs25 immunized
mouse showed significant transmission blocking activity, as
measured by the fall in oocyst number in the mosquitoes which
fed on antiserum from the Pfs25 immunized mouse compared to
the control (figure 7). This mouse had a moderate ELISA total IgG
titer of 1833 (geometric mean result for group 1664) so was
representative of expected responses. Dose dependent inhibition
was observed for both infection intensity (1 in 5: 96.0% inhibition;
1 in 10: 86.1%; 1 in 100: 42.3%), and infection prevalence (1 in 5:
78.3% inhibition; 1 in 10: 45.5%; 1 in 100: 24.8%). Statistically
significant inhibition was demonstrated at serum dilutions of 1 in 5
(P,0.0005) and 1 in 10 (P,0.01) but not at a dilution of 1 in 100.
Correlations with IgG were not assessed as serum from a single
representative mouse was used in this assay.
Discussion
Here we describe the successful induction of functional
transmission-blocking antibody responses directed against Pfs25
Figure 2. Pfs25 specific IgG isotype responses following Ad-
MVA Pfs25 immunization. BALB/c mice were immunized with Ad-
MVA Pfs25 as in figure 1a. Mice were immunized in two separate
experiments and the data show pooled responses (n = 17–20).
Individual isotype IgG responses against recombinant Pfs25 protein
were measured by ELISA in the serum of mice taken at 2 weeks
following final immunization. Individual and mean OD results are shown
for samples measured at a dilution of 1 in 500. Positive (immune) and
negative (non-immune) control sera were included in all assays. IgG3
was undetectable at this dilution.
doi:10.1371/journal.pone.0029428.g002
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following immunization with viral vectored vaccines recombinant
for P. falciparum P25 (Pfs25). Immunization of mice with our
previously reported AdHu5 prime – MVA boost regime
[21,23,25] resulted in high, antigen-specific antibody titers that
reacted with Pfs25 protein expressed by the Pfs25DR3 ookinete.
ChAd63 Pfs25 prime appeared to be as effective as AdHu5 Pfs25
as assessed by ELISA. Previous studies using the same vaccine
delivery platform have shown that IgG responses are maintained
over time in mice, rabbits and humans [23,25,28,46] – this is a
particularly important consideration for TBV design, and it will
be essential in future studies to assess maintenance of TBA over
time as well as immediately following a booster immunization.
Here we used a standardized ELISA in order that our results
would be comparable with other studies [39] and were able to
show that the levels of antibody titers achieved using this viral
vectored regime at the peak of the response were similar to those
recorded in studies of a Pfs25 protein-in-adjuvant vaccine
following one or two immunizations in mice [19,47]. Our
vaccine regime thus enables the production of similar antibody
levels without the need for potentially reactogenic adjuvants.
Although higher titers, of approximately 5000–20000 ELISA
units, have been reported elsewhere, the samples used in that
study were specifically selected for their high titers [40]. Further
comparison with other studies is limited by use of different ELISA
methods [34,48] or species [17].
Total IgG correlated inversely with oocyst intensity and
infection prevalence, and the predominant IgG isotypes induced
by Ad-MVA Pfs25 were IgG1 and IgG2a. Lower levels of IgG2b
were also detected, but not IgG3. Murine studies of both DNA
vaccines expressing Pfs25 and recombinant Pfs25 protein in
Alhydrogel and CpG adjuvant have shown predominance of both
IgG1 and IgG2a induction, although recombinant Pfs25 admin-
istered in Alhydrogel alone induced predominantly IgG1, with
little IgG2a [47,49,50]. Recombinant Pfs25 administered in
cholera toxin via the intranasal route led to production of
comparable levels of IgG1, IgG2a and IgG2b but little IgG3 [48].
Antibody effector mechanisms targeting Pfs25 within the mosquito
midgut could possibly involve ingested phagocytes and/or
Figure 3. Generation and phenotypic analysis of Pfs25DR3. (A) Schematic representation of the construction of Pfs25DR3. The targeting
plasmid was linearized by restriction digestion, and DNA was transfected into P. berghei ANKA 2.34. The P. berghei ORFs P25 and P28 were replaced
with the P. falciparum gene sequence of Pfs25 and the selectable marker cassette (TgDHFR/TS). (B) Diagnostic PCR on cloned transgenic Pfs25DR3.
(M: 500 bp marker; 1: 59 integration, oligos Int1+Int2; 2: 39 integration, oligos Int3+Int4; 3: Pf25 presence, oligos Pf25F+Pf25R; 4: Pb25 presence, oligos
Pb25F+Pb25R. (C) Western blot analysis of Pfs25DR3 ookinetes. Purified ookinetes (56107 per lane) were hybridized with anti-Pfs25/GFP serum from
Ad-MVA immunized mice. Loading control was carried out on stripped nitrocellulose membrane with anti-TAT-1 antibody at 1:10,000 (primary), and
anti-mouse IgG at 1:10,000 (secondary). Lane 1: P. berghei WT 2.34 ookinetes; Lane 2: P. berghei Pfs25DR3 ookinetes. (D) Expression and localization of
Pfs25 in the Pfs25DR3 transgenic parasite was confirmed via immunofluoresence assay on PFA fixed ookinetes.
doi:10.1371/journal.pone.0029428.g003
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complement within the first five hours following blood meal
uptake, alongside a more classical antibody neutralization
mechanism [7,51]. However it remains to be determined whether
induction of specific IgG isotypes is important with regard to TBA
mediated against the Pfs25 antigen.
Although strong antibody titers are of course desirable, the
functional effect of antibodies on oocyst intensity/infection
prevalence remains the ‘‘gold standard’’ readout to measure the
effectiveness of a potential TBV. Here we have employed a
proven transgenic parasite model [32] to compare the ability of
sera from vaccinated mice to affect oocyst development in the
SMFA as well as following live-feeding of mosquitoes on
immunized and infected mice. In this study, mosquitoes fed on
immunized mice showed a partial reduction in the level of a
chimeric Pfs25DR3 infection, leading to a significant reduction in
oocyst numbers in the fed mosquitoes of 67% and a reduction in
infection prevalence of 28%. A direct correlation was observed
between total IgG titer and oocyst numbers and prevalence of
Pfs25DR3. Mlambo et al. have previously shown protection
against a transgenic murine parasite expressing Pfs25
(TrPfs25Pb), by induction of Pfs25 antibodies following three
DNA Pfs25 immunizations in mice, but were unable to explore
the relationship between antibody titer and parasite infectivity
given only a single high titer serum was used in the reported
oocyst assays [32]. In a more recent study, they used the same
parasite to assess the efficacy of a recombinant baculovirus
expressing Pfs25 (AcNPV–Pfs25surf) and observed significant
reduction in prevalence and oocyst numbers following three
immunizations in mice [34]. The reduction in prevalence from
approximately 80% to 54% (following intramuscular immuniza-
tion of mice) or 65% (intranasal immunization) using AcNPV–
Pfs25surf was comparable to that observed here.
Immunized mouse serum also showed significant transmission
blocking activity (up to 96%) in a SMFA when fed to mosquitoes
with P. falciparum and a substantial reduction in infection
prevalence (78.3%). The use of a single mouse with a
Figure 4. Parasite infectivity (per mosquito) following Ad-MVA Pfs25 immunization. BALB/c mice were immunized with Ad-MVA Pfs25
(red) as figure 1a or Ad-MVA GFP (blue) a GFP-encoding control. Mice were divided into two groups and infected with (A) Pfs25DR3 (10 per group) or
(B) wild-type P. berghei (5 per group) and used to assess transmission to mosquitoes. Mosquito midguts were examined 12 days post-feeding. Data
points represent mosquitoes that fed on individual mice. X-axis points represent individual mice. Horizontal lines indicate the mean number of
oocysts for each mouse (+/2 sem).
doi:10.1371/journal.pone.0029428.g004
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representative titer is consistent with other studies in which sera
were pooled [30,52]. Given serum from just one mouse was used
for the SMFA it was not possible to correlate results with antibody
titer, but the serum clearly showed more inhibitory effect when a
higher concentration was used in the assay. Mlambo et al. observed
a 50% reduction in P. falciparum oocyst number, as measured in a
SMFA using mouse sera at an unspecified dilution [32]. The same
group showed .90% inhibition using rabbit sera in a SMFA [34].
Arakawa et al. found a reduction in oocyst number to zero at
dilutions of 1 in 2 to 1 in 32 using an inhaled recombinant Pfs25
protein vaccine, although the control oocyst count was relatively
low [48].
Here we found a strong reduction in P. falciparum oocyst
number at low serum dilutions of 1 in 5 to 1 in 10 (96% and
86.1% respectively), however the reduction in infection intensity
and prevalence was less pronounced when using the chimeric P.
berghei system but in agreement with this result, average oocyst
intensities in the murine model were approximately ten-fold
higher. Conversely, Mlambo et al. detected higher transmission
block activity with chimeric challenge than with SMFA [32], as
did Blagborough et al. [35]. It is not clear whether chimeric
challenge or SMFA is more predictive of vaccine efficacy in
humans, and vaccine efficacy measures in both systems will likely
be affected by overall infection intensity. Interestingly, in one
study it was found that the prevalence of infection when
mosquitoes were fed via membrane feeders was approximately
one third of that seen by direct feeding of mosquitoes on
volunteers and no assessment was made of the impact of feeding
method on oocyst number [53]. Further investigation is clearly
required to directly compare live-biting and SMFA readouts in
Figure 5. Parasite prevalence (per mouse) following Ad-MVA Pfs25 immunization. The same mosquitoes from figure 4 were analyzed for
oocyst prevalence. Data points represent the prevalence of oocyst infection in mosquitoes that fed on individual mice, expressed as a percentage of
total mosquitoes dissected.
doi:10.1371/journal.pone.0029428.g005
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relation to vaccine efficacy in both the P. berghei and P. falciparum
systems.
The clinical development of protein-in-adjuvant vaccines,
including those targeting Pfs25 and Pvs25 [17,54], has been
limited by the side effects and uncertain safety profile associated
with experimental adjuvants. On the basis of this and related
studies [26,30], we suggest viral vectored vaccines may therefore
provide a promising alternative and clinically-relevant means of
delivering comparable antibody immunogenicity for TBV candi-
date antigens. Indeed this vaccine platform has reliably induced
antibody immunogenicity against the MSP1 and AMA1 blood-
stage malaria antigens in mice, rabbits, rhesus macaques and
humans [21,22,25,26,28], and further studies in mice and rhesus
macaques have indicated that combining the protein and viral
vectored subunit vaccine platforms may allow for the induction of
even higher antibody titers [26,46,55]. The induction of extremely
high titer IgG responses in humans by TBVs, that need to be
maintained over the transmission season, may ultimately require
the adoption of regimes that utilize combined vaccine delivery
platforms. It is possible that a regime incorporating ChAd63-MVA
Pfs25 and/or followed by Pfs25 protein would induce higher
antibody titres and levels of protection in vivo than those observed
here, and further work is ongoing in order to investigate such an
approach.
Despite significant progress in recent years, there remains no
licensed vaccine to protect against malaria infection or to help
reduce transmission. Vaccines that act to prevent malaria
transmission are likely to be of use in combination with existing
malaria control measures (IRS, ITNs, ACTs) as well as other
candidate vaccines that are currently in development against the
liver- and blood-stages of infection [56,57]. The data described
here, generated using two different assay readouts, confirm the
utility of the Pfs25 antigen to exert TBA and encourage the
future clinical development of such viral vectored vaccine
candidates that could be trialled alone or in combination with
pre-existing protein vaccine candidates. Additionally, viral
vectors encoding transmission blocking sexual- and mosquito-
stage antigens could readily be combined, either in the same
vector or as a mixture, with vectors encoding protective liver-
stage and blood-stage antigens to provide a multi-stage vaccine.
The ease of recombinant viral vector generation, especially for
more difficult malaria antigens, also encourages the future
screening of TBV candidate antigens utilizing this platform to
generate antigen-specific IgG for testing in the SMFA. Such
future studies could allow for the most efficacious TBV candidate
antigen combination(s) to be taken forward for further clinical
development.
Figure 7. Parasite infectivity via membrane feeding asssay (per mosquito) following Ad-MVA Pfs25 immunization. Sexually mature P.
falciparum NF54 cultures were mixed with anti-Pfs25 serum from a representative Ad-MVA immunized mouse (Pfs25) or negative control anti-GFP
serum (GFP) at final dilutions of 1 in 5, 1 in 10 and 1 in 100. Data points represent the number of oocysts found in individual mosquitoes 12 days post
feed. Horizontal lines indicate the mean number of oocysts (+/2sem).
doi:10.1371/journal.pone.0029428.g007
Figure 6. Total IgG antibody titer correlates with oocyst
number. BALB/c mice (n = 10) were immunized with Ad-MVA Pfs25
and infected with Pfs25DR3 as previously (figures 4 & 5). Mean oocyst
number (circles) and the prevalence of infection (squares) were
calculated per mouse as shown in figures 4a and 5a. These data are
shown plotted against specific anti-Pfs25 total IgG titer for each mouse.
doi:10.1371/journal.pone.0029428.g006
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